Onconephrology

Questions discussed in this category

How would you approach dose modifications and/or frequency of lenalidomide in patients with advanced renal impairment (eGFR <30)?

The FDA package insert suggests 2.5 mg daily in these settings, while the PrE1003 study demonstrated that a higher dose is feasible. Many oncologists ...

2 Answers available

What is your approach to ESA use in patients with ESKD and active malignancy on treatment?

2 Answers available

Do you prefer monitoring creatinine over cystatin C levels in patients with lymphoma and chronic kidney disease given the potential for cystatin C levels to be increased with certain malignancies?

Hammouda et al., PMID 28282874

1 Answer available

Do you prefer assessing cystatin C or creatinine when monitoring a patient’s eGFR who is receiving chemotherapy for malignancy?

1 Answer available

Do you have a higher threshold regarding when to hold bevacizumab for proteinuria in patients who had known baseline proteinuria from diabetic nephropathy?

2 Answers available

Would you recommend initiating a SGLT2i for proteinuria secondary to bevacizumab in a patient who has a sub-optimal response to an ACEi or ARB?

2 Answers available

What is the management strategy for patients who develop AKI and nephrotic range proteinuria secondary to biopsy proven FSGS during immune checkpoint inhibitor therapy?

1 Answer available

Would you offer adjuvant immunotherapy in a patient with high risk RCC with new/worsening post-op renal dysfunction and CrCl<30?

KEYNOTE-564 required CrCl 30 or above. Not having a baseline/stable CrCl may make it difficult to diagnose or treat IO nephritis.

1 Answer available

Do you recommend a kidney biopsy for patients who develop acute kidney injury after starting sacituzumab?

1 Answer available

How do you manage patients blood pressures while on anti-angiogenic TKIs?

Do you insist on ambulatory/home blood pressures to rule in/out white coat hypertension? Does your practice have a system to log patients' BPs to supp...

1 Answer available

What are your management strategies for acute kidney injury attributed to pembrolizumab in patients with a kidney biopsy showing predominately acute tubular injury?

2 Answers available

What are your next steps for managing biopsy-proven interstitial nephritis from checkpoint inhibitors in patients who do not have a response to prednisone?

3 Answers available

Do you recommend preloading with IV magnesium to decrease the risk of cisplatin nephrotoxicity?

3 Answers available

What are your top takeaways from ASN 2023?

2 Answers available

Do you consider hyperuricemia as a potential etiology of an anion gap metabolic acidosis in patients with elevated uric acid levels and no other readily explainable causes of acidosis?

1 Answer available

Are there preventative measures that you take in your cancer patients with chronic kidney disease who require periodic iodinated contrast CT studies for monitoring of their malignancy?

2 Answers available

Do you recommend a kidney biopsy in a patient with myelodysplastic syndrome diagnosed two years prior who develops new onset proteinuria?

1 Answer available

What factors should prompt a kidney biopsy to evaluate for monoclonal gammopathy of renal significance in a patient with MGUS and suspected chronic diabetic nephropathy?

1 Answer available

How frequently do you monitor urine protein levels in a patient receiving bevacizumab who develops proteinuria of less than 2 grams per day?

2 Answers available

Do you recommend performing a kidney biopsy in patients with suspected ifosfamide nephrotoxicity?

1 Answer available

Would you recommend initiating RRT in a patient with tumor lysis syndrome and a phosphorus of 9 mg/dl or more who does not have symptomatic hypocalcemia or other indications for dialysis?

1 Answer available

Should CAR-T therapy be considered for a kidney transplant patient with refractory PTLD?

1 Answer available

How do you manage hyponatremia in patients with renal cell carcinoma on cabozantinib and nivolumab?

2 Answers available

When do you perform a kidney biopsy in a patient with AKI that is thought to be related to an immune checkpoint inhibitor?

Do you wait to monitor response to empiric corticosteroids before pursuing a kidney biopsy?

2 Answers available

Do you recommend testing for G6PD deficiency in those with whom rasburicase for tumor lysis syndrome is indicated?

2 Answers available

Do you recommend retreatment with an immune checkpoint inhibitor in a patient with a history of immune checkpoint inhibitor-related AKI that resolved with holding the immune checkpoint inhibitor and a glucocorticoid taper?

3 Answers available

Papers discussed in this category

Kidney international reports, 2021 Jan 06

Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes.

Cancer, 2017-06-01

Immune checkpoint inhibitors in challenging populations.

N Engl J Med,

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Cancers, 2022 May 17

Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers.

International journal of urology : official journal of the Japanese Urological Association, 2023 Jun 06

Tolerability of immune checkpoint inhibitor doublet for advanced renal cell carcinoma patients with pre-dialysis chronic kidney disease or end-stage renal disease.

Journal for immunotherapy of cancer, 2020 Oct

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab.

Clinical journal of the American Society of Nephrology : CJASN, 2024 Jun 07

Assessment of Glomerular Filtration Rate in Patients with Cancer: A Statement from the American Society of Onco-Nephrology.

Blood, 2011-09-15

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.

Haematologica, 2011 Dec 01

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.

Cancer Chemother Pharmacol, 2016 Jun 10

Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.

Clin Cancer Res, 2020 Aug 17

Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation.

Clinical pharmacokinetics, 2017 Feb

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.

Cancer chemotherapy and pharmacology, 2016 Dec 30

Population pharmacokinetics of lenalidomide in multiple myeloma patients.

Related Topics